IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 24, 2024 08:00 ET
|
IN8bio, Inc
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 13, 2024 16:01 ET
|
IN8bio, Inc
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
June 03, 2024 06:05 ET
|
IN8bio, Inc
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
May 24, 2024 08:00 ET
|
IN8bio, Inc
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
May 23, 2024 17:00 ET
|
IN8bio, Inc
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
May 14, 2024 10:00 ET
|
IN8bio, Inc
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
May 13, 2024 08:00 ET
|
IN8bio, Inc
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 09, 2024 16:00 ET
|
IN8bio, Inc
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 30, 2024 06:05 ET
|
IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 24, 2024 08:00 ET
|
IN8bio, Inc
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting